Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells.

de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P, Hancock WW.

Mol Cell Biol. 2011 May;31(10):2066-78. doi: 10.1128/MCB.05155-11. Epub 2011 Mar 28.

2.

Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.

Beier UH, Akimova T, Liu Y, Wang L, Hancock WW.

Curr Opin Immunol. 2011 Oct;23(5):670-8. doi: 10.1016/j.coi.2011.07.002. Epub 2011 Jul 26. Review.

3.

Histone deacetylase inhibitors and transplantation.

Tao R, de Zoeten EF, Ozkaynak E, Wang L, Li B, Greene MI, Wells AD, Hancock WW.

Curr Opin Immunol. 2007 Oct;19(5):589-95. Epub 2007 Aug 24. Review.

4.

Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.

Hancock WW.

Handb Exp Pharmacol. 2011;206:103-23. doi: 10.1007/978-3-642-21631-2_6. Review.

PMID:
21879448
5.

Drugging the HDAC6-HSP90 interplay in malignant cells.

Krämer OH, Mahboobi S, Sellmer A.

Trends Pharmacol Sci. 2014 Oct;35(10):501-9. doi: 10.1016/j.tips.2014.08.001. Epub 2014 Sep 16. Review.

PMID:
25234862
6.

Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance.

Wang L, Tao R, Hancock WW.

Immunol Cell Biol. 2009 Mar-Apr;87(3):195-202. doi: 10.1038/icb.2008.106. Epub 2009 Jan 27. Review.

PMID:
19172156
7.

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.

Wang L, de Zoeten EF, Greene MI, Hancock WW.

Nat Rev Drug Discov. 2009 Dec;8(12):969-81. doi: 10.1038/nrd3031. Epub 2009 Oct 26. Review.

8.

Immune regulation by histone deacetylases: a focus on the alteration of FOXP3 activity.

Zhang H, Xiao Y, Zhu Z, Li B, Greene MI.

Immunol Cell Biol. 2012 Jan;90(1):95-100. doi: 10.1038/icb.2011.101. Epub 2011 Nov 29. Review.

9.

Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function.

Xiao Y, Li B, Zhou Z, Hancock WW, Zhang H, Greene MI.

Curr Opin Immunol. 2010 Oct;22(5):583-91. doi: 10.1016/j.coi.2010.08.013. Epub 2010 Sep 24. Review.

10.

FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance.

Dummer CD, Carpio VN, Gonçalves LF, Manfro RC, Veronese FV.

Transpl Immunol. 2012 Jan;26(1):1-10. doi: 10.1016/j.trim.2011.08.009. Epub 2011 Sep 13. Review.

PMID:
21939765
11.

HDAC inhibitor therapy in autoimmunity and transplantation.

Hancock WW, Akimova T, Beier UH, Liu Y, Wang L.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i46-54. doi: 10.1136/annrheumdis-2011-200593. Review.

PMID:
22460138
12.

Histone deacetylase 6 in health and disease.

Seidel C, Schnekenburger M, Dicato M, Diederich M.

Epigenomics. 2015;7(1):103-18. doi: 10.2217/epi.14.69. Review.

PMID:
25687470
13.

Regulatory cells and transplantation tolerance.

Cobbold SP, Waldmann H.

Cold Spring Harb Perspect Med. 2013 Jun 1;3(6). pii: a015545. doi: 10.1101/cshperspect.a015545. Review.

14.

Control of Regulatory T Cell Migration, Function, and Homeostasis.

Campbell DJ.

J Immunol. 2015 Sep 15;195(6):2507-13. doi: 10.4049/jimmunol.1500801. Review.

15.

HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

Simões-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M.

Mol Neurodegener. 2013 Jan 29;8:7. doi: 10.1186/1750-1326-8-7. Review.

16.

HDAC6: physiological function and its selective inhibitors for cancer treatment.

Yang PH, Zhang L, Zhang YJ, Zhang J, Xu WF.

Drug Discov Ther. 2013 Dec;7(6):233-42. Review.

17.

HDAC6 and ovarian cancer.

Haakenson J, Zhang X.

Int J Mol Sci. 2013 May 2;14(5):9514-35. doi: 10.3390/ijms14059514. Review.

18.

[Histone deacetylase 6: structure, functions and development of selective inhibitors].

Liu RS, Fang H.

Yao Xue Xue Bao. 2015 Jan;50(1):7-14. Review. Chinese.

PMID:
25924468
19.

The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.

Batchu SN, Brijmohan AS, Advani A.

Clin Sci (Lond). 2016 Jun 1;130(12):987-1003. doi: 10.1042/CS20160084. Review.

PMID:
27154743
20.

Beyond the Selective Inhibition of Histone Deacetylase 6.

Rodrigues DA, Thota S, Fraga CA.

Mini Rev Med Chem. 2016;16(14):1175-84. Review.

PMID:
27121714
Items per page

Supplemental Content

Write to the Help Desk